Trial Profile
Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms PAPE
- 27 May 2020 Results (n=45) assessing relationship between the predictors and the hormonal and tumoral responses to long-acting pasireotide (PAS-LAR) therapy compared with responsiveness to first-generation somatostatin receptor ligands, published in the European Journal of Endocrinology.
- 18 Mar 2019 Results assessing T2-signal intensity and SST receptor expression in relation to the hormone and tumor response during PAS-LAR treatment presented at the 101st Annual Meeting of the Endocrine Society
- 12 Oct 2018 Results (n=59) of the extension study of 48 weeks ,published in the European Journal of Endocrinology